Owner Scorecard


← All companies ← FBRT Manual FBYD → ← FBIOP Pharmaceuticals GERN →

FBRX, Forte Biosciences Inc.

Pharmaceuticals consumer brand UnprofitableDistress / turnaroundNet current asset value

Forte Biosciences, Inc. is a clinical-stage biopharmaceutical company whose current lead product candidate is FB102.

Based on the successful completion of the Phase 1 healthy volunteer cohorts, we initiated a patient-based Phase 1b trial in celiac disease in the third quarter of 2024 and a patient-based Phase 1b trial for non-segmental vitiligo in the first quarter of 2025.

Latest annual: FY2025 10-K
FBRX · Forte Biosciences Inc.
I

The business

What it sells, where the money comes from, the kind of company it is.

Revenue · FY2025
$36K
−99.8% YoY · −10% 3-yr CAGR
Vital signs · FY2025
Cash & investments $113M
Cash burn · annual $51M
Runway 2.2 yrs

The business in brief

read the 10-K →

What this business is and what moves its needle, from its own SEC filings.

Situation
Unprofitable. No meaningful revenue yet; the record is the cash on hand against the burn. Distress / turnaround. Thin interest coverage, or operating cash burned against real debt, across the record. The balance sheet carries this situation; the debt schedule sets the clock. Net current asset value. Current assets alone exceed every liability combined, and the surplus is most of the balance sheet: the shape Graham called a net-net.
What moves the needle
Operating margin has run around −64673% through the cycle, the operating line deeply negative — so the lever is the path to a margin at all: revenue growth against the cost curve and the cash runway, not the level of a margin that isn't there yet. Capital spending runs about 450% of sales, well above depreciation, so the return earned on what it sinks into that plant weighs as much as the margin. Read this kind of business on the pipeline against the patent cliff, and pricing. On its own account, the filing leans hardest on pricing power & competition, set against the numbers in what the filing emphasizes, below.

Every line is arithmetic on the company's filings, shown in full in the sections below.

II

The record

Ten years of arithmetic, read across the cycle.

The record, 2016–2019

realized figures from each filing · older years to the left
2016’162017’172018’182019’19
Income statement
$49K$41K$18M$36KRevenueRevenue
n/mn/m71%n/mSG&A / revenueSG&A/rev
n/mn/m283%n/mR&D / revenueR&D/rev
($32M)($38M)($46M)($4M)Operating incomeOp. inc.
n/mn/m−254.2%n/mOperating marginOp. mgn
($33M)($39M)($49M)($4M)Net incomeNet inc.
Cash flow & returns
($30M)($31M)($34M)($3M)Operating cash flowOp. cash
$255K$292K$625K$11KDepreciationDeprec.
$2M$3M$7M$1MWorking capital & otherWC & other
$525K$655K$2M$162KCapexCapex
n/mn/m10.9%450.0%Capex / revenueCapex/rev
($30M)($32M)($36M)($3M)Owner earningsOwner earn.
n/mn/m−202.0%n/mOwner earnings marginOE mgn
($30M)($32M)($36M)($3M)Free cash flowFCF
n/mn/m−202.0%n/mFree cash flow marginFCF mgn
Balance sheet
$6M$36M$41M$7MCash & investmentsCash+inv
$2M$2M$3M$2MAccounts payablePayables
$32M$91M$98M$8MCurrent assetsCur. assets
$14M$17M$17M$2MCurrent liabilitiesCur. liab.
2.3×5.2×5.9×3.9×Current ratioCurr. ratio
$35M$92M$103M$8MTotal assetsAssets
$10M$4M$26MTotal debtDebt
$5M($32M)($15M)Net debt / (cash)Net debt
($124M)$71M($736K)($5M)Shareholders’ equityEquity
n/mn/m38.1%100.0%Stock comp / revenueSBC/rev
Per share
2.2M14.6M20.1M2.1MShares out (diluted)Shares
$0.02$0.00$0.90$0.02Revenue / shareRev/sh
$-15.22$-2.66$-2.44$-1.93EPS (diluted)EPS
$-13.67$-2.18$-1.82$-1.39Owner earnings / shareOE/sh
$-13.67$-2.18$-1.82$-1.39Free cash flow / shareFCF/sh
$0.24$0.04$0.10$0.08Cap. spending / shareCapex/sh
$-56.55$4.87$-0.04$-2.26Book value / shareBVPS

The diluted share count moved ×6.64 into 2017 — shares issued, not a split the totals corroborate — and the per-share figures carry the counts as filed.

The diluted share count moved ×1/9.51 into 2019 — shares retired, not a split the totals corroborate — and the per-share figures carry the counts as filed.

Per-share growththe realized rate an owner's share compounded
3-yr5-yr
Revenue / share−8.5%/yr−8.5%/yr (3-yr)
Capital spending / share−31.5%/yr−31.5%/yr (3-yr)

The record, charted

FY2016–2019

Each measure over its full record; the current point and the worst year marked.

Share count
2Mpeak FY2018

Owner earnings vs. net income

Owner earningsNet income

The accountant's number, and the cash an owner can take; the gap is the tell.

($3M)owner earningsvs.($4M)net incomelow FY2018

Net income is the accountant's number; owner earnings is the cash an owner could take out. The walk between them, off the cash-flow statement, and whether the gap is widening or holding.

In fiscal 2019 the business turned a $4M loss into ($3M) of owner earnings: more cash than the profit line showed, after the non-cash charges and the capital it put back in.

FY2019FY2018FY2017FY2016
Reported net income($4M)($49M)($39M)($33M)
Depreciation & amortizationnon-cash charge added back+$11K+$625K+$292K+$255K
Stock-based compensationreal costnon-cash, but a real cost+$36K+$7M+$4M+$1M
Working capital & othertiming of cash in and out, other non-cash items+$1M+$7M+$3M+$2M
Cash from operations($3M)($34M)($31M)($30M)
Capital expenditurecash put back in to keep running and to grow−$162K−$2M−$655K−$525K
Owner earnings($3M)($36M)($32M)($30M)
Owner-earnings marginowner earnings ÷ revenue-8147%-202%-77532%-61355%

Owner earnings is the cash an owner could pull out without starving the business: operating cash less the capital it must spend to hold its position . The cash-flow statement also adds stock comp back as non-cash, but it is a real cost paid in shares; counted as the expense it is (less $36K), owner earnings is nearer ($3M).

Maintenance capex is estimated as depreciation where a growing business invests above it; free cash flow is the figure the scorecard's free-cash margin reads.

III

Quality & stewardship

Returns, the balance sheet, capital allocation, and pay.

Owner’s Scorecard

FY2025 10-K · source on SEC EDGAR →
Material weakness in financial controls
“During the audit process related to Forte's fiscal year ended December 31, 2022, management identified a material weakness in Forte's controls related to the review of the annual income tax provision which had been prepared by a third-party accounting firm…”

The figures below are only as sound as the controls that produced them. read the note →

Will it survive?

  • No meaningful interest burden
    Little or no interest expense reported
    What this means

    Little or no interest expense reported, the business isn't leaning on lenders to operate.

  • Net cash
    Cash $77M + ST investments $36M − debt $26M
    What this means

    Cash and short-term investments exceed every dollar of debt by $87M, on net the company owes nothing, and can act from strength when others can't. Net debt is the leverage figure that matters: the cash is already set against the debt. Strategic or illiquid investments aren't counted here.

  • Not enough data
    What this means

    The filing data didn't include the inputs for this check.

Is it a good business?

  • Below average
    NOPAT ($56M) ÷ invested capital $10M (debt + equity − cash)
    Industry peers: median -97%
    What this means

    The rate the business earns on the money tied up in it, Buffett's north star, because over time a stock tracks the ROIC beneath it. Above ~15% sustained hints at a moat; a return below the cost of capital (~8%) erodes value as a business grows rather than building it — the test Buffett weighs most. Asset-light businesses (R&D expensed, little capital) read artificially high, pair this with Owner Earnings.

  • Consumes cash through the cycle
    4-yr median margin, range -77532%–-202%; latest ($51M) = operating cash ($51M) − maintenance capex $116K
    Industry peers: median -10717%
    What this means

    What an owner could take out without starving the business: operating cash less the maintenance capital it must spend to hold its position — Buffett's owner earnings. That's -141661% of revenue this year, a -61355% median across 4 years. Treating stock comp as the real expense it is (less $6M of SBC) leaves ($57M).

  • Loss, and burning cash
    Net income ($69M) · cash from operations ($51M)

    In the filing’s words The filing discloses a material weakness in its financial controls — the reported numbers here, and the record built on them, are only as reliable as the controls that produced them.

    What this means

    The company reported a net loss, so a conversion ratio isn't meaningful. What matters then is whether operations still threw off cash, here, they did not.

How is the cash used?

  • Not enough data
    What this means

    The filing data didn't include the inputs for this check.

  • Investing or harvesting? 1.81×
    Expanding
    Capex $116K ÷ depreciation $64K
    What this means

    Descriptive, not a grade. Above ~1× means investing faster than assets wear out (growth, or, sustained for years, today's earnings carrying less depreciation than tomorrow's will). Below means spending less than it's wearing out (efficiency, or a melting asset base). The ratio won't tell you which; the filings will.

Graham’s defensive tests · 2 of 3 met

Graham’s numerical criteria for the defensive investor (The Intelligent Investor, ch. 14), run on the filings. A floor of safety, not a buy signal; many fine modern businesses fail his strictest liquidity rules by design.

  • Adequate size Miss
    Revenue ≥ $2B · $36K
    What this means

    Big enough to weather a storm. Graham's 1972 floor was ~$100M of sales (≈ $700M today); we use a $2B revenue line as a conservative modern stand-in.

  • Strong liquidity Pass
    Current ratio ≥ 2× · 3.88×
    What this means

    Current assets at least twice current liabilities, near-term bills covered without touching the business. Strict by design: many cash-rich modern firms run leaner and miss it, holding their cushion in longer-dated securities.

  • Conservative debt Pass
    Debt ≤ working capital · $26M vs $60M WC
    What this means

    Graham's rule that borrowings not exceed net current assets. Capital-heavy and buyback-heavy firms routinely fail it, read it next to interest coverage, not alone.

  • Moderate price
    P/E ≤ 15 and P/E × P/B ≤ 22.5 · decided by the price
    What this means

    Graham's valuation gate, the wall he kept between a sound business and a sound investment. Three-year average earnings are $-2.37/share (latest year $-5.36), the averaged base the calculator's gate runs on, and book value is $4.71/share. Enter a price in “What the price implies” just below for the P/E, P/B, and whether it clears. But this is the rule Buffett outgrew: there's no hard P/E law, and a wonderful business can deserve a far richer multiple if the thesis holds, treat it as the bargain-hunter's floor, not a verdict on the price.

Durability & moat, 2016–2019

Whether the record’s returns held, and what the capital reinvested earned.

  • Profitable years 0 of 4
    What this means

    Lost money in 4 year(s), look at what happened there before trusting the average.

  • Operating margin −78225% → −5772% (2-yr avg ends)

    In the filing’s words The margin widened even though the filing names price competition — the gain came from volume or cost, not pricing power. Read where.

    What this means

    Through the cycle the operating margin widened — about −78225% early to −5772% lately, median −64673% — pricing power intact or improving.

  • Reinvestment, incremental ROIC returns capital
    What this means

    The capital base barely grew: this business returns cash through dividends and buybacks rather than reinvesting. Judge it on the cash returned, not on compounding.

  • Worst year 2017 · −91775.6% op. margin
    What this means

    Operations went underwater in 2017, understand why before trusting the good years.

  • Share count −1.4%/yr
    What this means

    The share count is shrinking, buybacks are quietly growing your slice of the business.

Does AI threaten the moat?

Low contestability

The moat is physical, regulated or balance-sheet-funded, the kind AI cuts costs within but does not contest.

In its own filing Framed as a capability

The filing positions AI as something the company uses, not something it fears.

“Moreover, advancements in technology, such as artificial intelligence and machine learning, are changing and may continue to change the way companies are subjected to attempts to gain unauthorized access and disrupt systems, thereby increasing the risks of security threats and at…”

AI is unlikely to contest a moat that is physical, regulated or balance-sheet-funded; here it reads more as a cost tool than a threat, and the company is using it that way.

Read from the filing's own risk factors, paired with the industry's structure under its SIC code; the durability is read above, the price below.

All figures as filed; the source filing is linked above.

Current Position

as of the latest quarter, Mar 31, 2026

Can the business pay what it owes this year, off the freshest balance sheet: the quality of the assets, the debt actually coming due, and what a low ratio means here.

Current assets$65M
  • Cash & short-term investments$94M
Current liabilities$24M
  • Accounts payable$13M
  • Other current liabilities$11M
Current ratio2.75×all current assets ÷ what's due · Graham looked for 2×
Quick ratioinventory untagged this quarter, so withheld rather than shown equal to the current ratio
Cash ratio3.99×strictest: cash alone against what's due
Working capital$41Mthe cushion left after near-term bills
Current ratio, recent quarters2.8× → 2.8×
Deeper floors
Tangible book value$42Mequity stripped of goodwill & intangibles
Net current asset value$40MGraham's net-net: current assets less all liabilities
Debt incl. operating leases$26M$4M of it operating leases
Deferred revenue$18Kcustomer cash collected before delivery; operating float

From the company's latest filing.

Management, ownership & pay

read the proxy →

From the proxy: how much of the business the people running it own, and how they are paid, beside what the business earned for its owners in the same years.

Fiscal yearChief executivePay, as filed“Actually paid”Net income
2023Dr. Paul Wagner$1.5M$1.4M
2024Dr. Paul Wagner$1.7M$1.9M
2025Dr. Paul Wagner$7.4M$17.8M

Both pay figures are the company’s own, from the pay-versus-performance table its proxy statement files. “As filed” is the Summary Compensation Table total: salary, bonus, and equity awards at their value on the day of grant. “Actually paid” is the SEC’s prescribed recalculation, which re-marks those equity awards to what they became as they vested; it can swing far above or below the filed figure in either direction, and negative years occur. Net income is the whole business's, as filed, for the same fiscal years.

  • Insider ownership4.4%

    The stake all directors and executive officers hold together, per the 2026 proxy: skin in the game, the first thing Munger reads.

  • Stock-based compensation$6M

    The slice of the business handed to employees in shares this year, 17383% of revenue. Buffett's oldest accounting fight: this is compensation, compensation is an expense, real whether or not the headline earnings admit it. One trap: the cash-flow statement adds SBC back, so the operating cash, and the owner earnings drawn from it, are flattered by exactly this amount; counted as the cost it is, what an owner keeps is lower.

What an owner would ask, FY2025

read the 10-K →
  • Which reported numbers are a judgment call?
    Management names Stock compensation as critical estimates

    each rests partly on management's judgment; the filing's note sets out the assumptionsverify →

The questions the record and the charts do not answer on their own; each carries the figure and the place to look.

Peers, Pharmaceuticals

The same industry, side by side on owner economics. Each figure is a through-cycle median, so a peak or trough year can’t distort it; the group median at the foot is the line to read each against.

CompanyRevenueGross marginOp. marginROICOwner earn. margin
SGMTSagimet Biosciences Inc. Series A$2M-2844.5%-59%
GERNGeron Corporation$237K-5666.5%-30%-6875%
CADLCandel Therapeutics Inc.$125K-20580.8%-17960%
IXHLIncannex Healthcare Inc.$86K-27661.6%-14559%
CNTBConnect Biopharma Holdings Limited$64K-90740.6%-1262%-80688%
AVTXAvalo Therapeutics Inc.$59K63%-1241.0%-97%-606%
ALTAltimmune Inc.$41K-577.1%-105%-189%
FBRXForte Biosciences Inc.$36K-37981.2%-545%-34751%
Group median-13123.7%-101%-14559%
IV

The price

What a price has to assume.

What the price implies

reverse-DCF

Forte Biosciences Inc. is profitable, but owner earnings are negative this year because capital spending currently outruns operating cash, a build-out, so the owner-earnings reverse-DCF has no positive base to grow. We read the price from both ends instead: type a price to see the steady-state profitability it demands, then set the mature margin you would believe and weigh the two against each other. Nothing leaves your browser unless you enter it in your notebook.

$
The assumptions

Revenue, delivered68%/yr’16→’19

Enter a price to run it.

Owner earnings it must reach
Margin the price demands
Owner-earnings margin today−141661%

Two reads of one future. From your price: the owner earnings the company must reach, valued at a mature multiple and discounted back at your rate, expressed as the margin it implies on revenue grown at your rate. From your belief: the mature margin you would credit, set on the dial above. When the margin the price demands runs above the one you would believe, you are paying for a future taken on faith. For a deep cyclical at a trough, normalized through-cycle earnings are the better lens; this mode is for the genuinely unprofitable, and for the profitable business whose capital spending currently outruns its cash.

Cite: Owner Scorecard, "Forte Biosciences Inc. (FBRX), the owner's record," https://ownerscorecard.com/c/FBRX, data as of 2026-07-09.

Manual order: ← FBRT its page in the Manual FBYD →

Industry order: ← FBIOP the Pharmaceuticals chapter GERN →